Publications by authors named "E Martin-Arranz"
Aims: The aim of the study is to evaluate the clinical and biochemical response of inflammatory bowel disease patients treated with vedolizumab, 16 weeks after transitioning from intravenous (iv) to subcutaneous (sc).
Methods: An observational, prospective, single-center cohort study was performed. Patients with inflammatory bowel disease and maintenance treatment with vedolizumab, stable for at least 4 months, were offered to switch to sc formulation.
Article Synopsis
- Limited data exist on the outcomes of inflammatory bowel disease (IBD) in patients who undergo solid organ transplantation (SOT), and this study examines both pre-existing IBD and newly developed IBD post-transplant.
- The study included 177 patients, of which 106 had pre-existing IBD, and found that 32% of these patients experienced disease progression after a median of 2.2 years, while 55% of those with de novo IBD progressed within 1.9 years.
- Key risk factors for progression in pre-existing IBD included having active disease at the time of SOT and extraintestinal manifestations, indicating a significant impact on patient outcomes post-transplant.*
Introduction: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. Our aim was to evaluate the predictive pharmacogenetic risk of pancreatitis in IBD patients treated with thiopurines.
Methods: We conducted an observational pharmacogenetic study of acute pancreatitis events in a cohort study of IBD patients treated with thiopurines from the prospectively maintained ENEIDA registry biobank of GETECCU.
Background: The rates of clinical and biochemical responses in Crohn's disease (CD) patients treated with intravenous (IV) ustekinumab (UST) intensification are scarcely described.
Methods: Patients with diagnosis of CD who were under intensified IV ustekinumab treatment (130 mg every 4 weeks) were retrospectively included, evaluating the clinical and biochemical response 12 weeks after the change in treatment regimen (switch from SC to IV), as well as the serum levels of the drug.
Results: Twenty-seven patients, all of whom had transitioned to intensified intravenous ustekinumab treatment due to a secondary loss of response to the drug, were included in the retrospective analysis.
Aim: Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with vedolizumab (VDZ) during induction in patients with moderate-severe UC and incomplete response to steroids.
Patients And Methods: Single-center retrospective review of patients receiving GMA+VDZ.